$RVNC
Revance Therapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000147929020000090 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $299.0K $0.00
YoY Change -100.0%
Cost Of Revenue $20.00K
YoY Change
Gross Profit $280.0K
YoY Change
Gross Profit Margin 93.65%
Selling, General & Admin $29.61M $13.60M
YoY Change 117.76% 6.77%
% of Gross Profit 10573.57%
Research & Development $27.10M $25.53M
YoY Change 6.18% 11.61%
% of Gross Profit 9679.64%
Depreciation & Amortization $1.410M $790.0K
YoY Change 78.48% 88.1%
% of Gross Profit 503.57%
Operating Expenses $56.71M $39.12M
YoY Change 44.95% 9.88%
Operating Profit -$57.11M -$39.12M
YoY Change 45.97% 12.04%
Interest Expense $4.256M $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$134.0K $115.0K
YoY Change -216.52% -166.86%
Pretax Income -$60.59M -$37.39M
YoY Change 62.05% 9.71%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$60.59M -$37.39M
YoY Change 62.05% 9.71%
Net Earnings / Revenue -20264.21%
Basic Earnings Per Share -$1.12
Diluted Earnings Per Share -$1.12 -$864.3K
COMMON SHARES
Basic Shares Outstanding 54.26M shares 44.01M shares
Diluted Shares Outstanding 54.26M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $494.0M $241.9M
YoY Change 104.22% 3.51%
Cash & Equivalents $363.5M $90.03M
Short-Term Investments $130.5M $151.9M
Other Short-Term Assets $7.900M $8.000M
YoY Change -1.25% -12.09%
Inventory $800.0K
Prepaid Expenses
Receivables $49.00K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $502.8M $249.9M
YoY Change 101.18% 2.89%
LONG-TERM ASSETS
Property, Plant & Equipment $13.70M $15.26M
YoY Change -10.27% 25.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.639M $2.392M
YoY Change -31.48% -27.84%
Total Long-Term Assets $73.41M $45.99M
YoY Change 59.63% 183.15%
TOTAL ASSETS
Total Short-Term Assets $502.8M $249.9M
Total Long-Term Assets $73.41M $45.99M
Total Assets $576.2M $295.9M
YoY Change 94.73% 14.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.603M $7.966M
YoY Change -17.11% 46.57%
Accrued Expenses $22.25M $14.74M
YoY Change 50.95% 8.61%
Deferred Revenue $12.26M $18.83M
YoY Change -34.9%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $47.99M $44.70M
YoY Change 7.38% 57.8%
LONG-TERM LIABILITIES
Long-Term Debt $174.3M $0.00
YoY Change
Other Long-Term Liabilities $98.20M $62.70M
YoY Change 56.62% 200.0%
Total Long-Term Liabilities $272.5M $62.70M
YoY Change 334.61% 200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $47.99M $44.70M
Total Long-Term Liabilities $272.5M $62.70M
Total Liabilities $320.5M $107.4M
YoY Change 198.52% 117.89%
SHAREHOLDERS EQUITY
Retained Earnings -$966.7M -$757.5M
YoY Change 27.62% 23.92%
Common Stock $1.222B $945.9M
YoY Change 29.22% 15.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $255.7M $188.5M
YoY Change
Total Liabilities & Shareholders Equity $576.2M $295.9M
YoY Change 94.73% 14.19%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$60.59M -$37.39M
YoY Change 62.05% 9.71%
Depreciation, Depletion And Amortization $1.410M $790.0K
YoY Change 78.48% 88.1%
Cash From Operating Activities -$17.21M -$29.29M
YoY Change -41.24% -19.89%
INVESTING ACTIVITIES
Capital Expenditures -$570.0K -$380.0K
YoY Change 50.0% -70.08%
Acquisitions
YoY Change
Other Investing Activities $94.47M $54.39M
YoY Change 73.69% 966.47%
Cash From Investing Activities $93.90M $54.01M
YoY Change 73.86% 1310.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 500.0K 40.00K
YoY Change 1150.0% -98.64%
NET CHANGE
Cash From Operating Activities -17.21M -29.29M
Cash From Investing Activities 93.90M 54.01M
Cash From Financing Activities 500.0K 40.00K
Net Change In Cash 77.19M 24.76M
YoY Change 211.75% -183.12%
FREE CASH FLOW
Cash From Operating Activities -$17.21M -$29.29M
Capital Expenditures -$570.0K -$380.0K
Free Cash Flow -$16.64M -$28.91M
YoY Change -42.44% -18.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001479290
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36297
dei Entity Registrant Name
EntityRegistrantName
Revance Therapeutics, Inc.
dei Entity Address Address Line1
EntityAddressAddressLine1
7555 Gateway Boulevard
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
363511000 USD
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0551645
dei Entity Address City Or Town
EntityAddressCityOrTown
Newark
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94560
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
742-3400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RVNC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65928296 shares
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
171160000 USD
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
130532000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
118955000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
49000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
778000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
0 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7901000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6487000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
502771000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
296602000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13695000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14755000 USD
CY2020Q2 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
31660000 USD
CY2019Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
0 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25366000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26531000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1050000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
730000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1639000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1669000 USD
CY2020Q2 us-gaap Assets
Assets
576181000 USD
CY2019Q4 us-gaap Assets
Assets
340287000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6603000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8010000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22245000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18636000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12255000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7911000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3789000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3470000 USD
CY2020Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3101000 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2952000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
47993000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40979000 USD
CY2020Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
174304000 USD
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
74295000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
47948000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23871000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25870000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
320463000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
114797000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57313556 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57313556 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52374735 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52374735 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
57000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1222271000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1069639000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
117000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-966727000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-844204000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
255718000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
225490000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
576181000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
340287000 USD
CY2020Q2 us-gaap Revenues
Revenues
299000 USD
CY2019Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
357000 USD
us-gaap Revenues
Revenues
278000 USD
CY2020Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
21000 USD
CY2019Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
0 USD
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
21000 USD
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
0 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27103000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25526000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66897000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49521000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29606000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13596000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50830000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26506000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
674000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
674000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2020Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
57404000 USD
CY2019Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
39122000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
118422000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
76027000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-57105000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-39122000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-118065000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-75749000 USD
CY2020Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
964000 USD
CY2019Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1596000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2455000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3166000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
4256000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
6404000 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q2 rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-59000 USD
CY2019Q2 rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
21000 USD
rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-149000 USD
rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-71000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-134000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
115000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-260000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-40000 USD
CY2020Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-60590000 USD
CY2019Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-37390000 USD
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-122423000 USD
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-72694000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-60590000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-37390000 USD
us-gaap Net Income Loss
NetIncomeLoss
-122523000 USD
us-gaap Net Income Loss
NetIncomeLoss
-72694000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-407000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
46000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
114000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
124000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60997000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37344000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-122409000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72570000 USD
CY2020Q2 rvnc Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-60590000 USD
CY2019Q2 rvnc Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-37390000 USD
rvnc Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-122523000 USD
rvnc Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-72694000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.27
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.71
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54257320 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43260317 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54062678 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42434137 shares
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
108510000 USD
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57313556 shares
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
255718000 USD
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44105474 shares
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
188542000 USD
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57313556 shares
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
255718000 USD
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44105474 shares
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
188542000 USD
us-gaap Net Income Loss
NetIncomeLoss
-122523000 USD
us-gaap Net Income Loss
NetIncomeLoss
-72694000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
11184000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13897000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8579000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4504000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2152000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1418000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1111000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1481000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-240000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-338000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
49000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-27000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
778000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1179000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2903000 USD
rvnc Increase Decreasein Operating Lease Rightof Use Assets
IncreaseDecreaseinOperatingLeaseRightofUseAssets
-1165000 USD
rvnc Increase Decreasein Operating Lease Rightof Use Assets
IncreaseDecreaseinOperatingLeaseRightofUseAssets
2938000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-30000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-853000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1099000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-321000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4052000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-914000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30692000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-278000 USD
rvnc Increase Decreasein Operating Lease Liabilities
IncreaseDecreaseinOperatingLeaseLiabilities
-1679000 USD
rvnc Increase Decreasein Operating Lease Liabilities
IncreaseDecreaseinOperatingLeaseLiabilities
2637000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60502000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40704000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
159412000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
164970000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1113000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1459000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
118000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
132000000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
117000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
16969000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11674000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49429000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
287500000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
rvnc Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount
ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount
15581000 USD
rvnc Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount
ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount
108100000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1670000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
480000 USD
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
28865000 USD
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9190000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1512000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1148000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
337000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
521000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
264847000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106911000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
192671000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16778000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171890000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73986000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
364561000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90764000 USD
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
43400000 USD
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
0 USD
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
159000 USD
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
1408000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-60600000 USD
us-gaap Net Income Loss
NetIncomeLoss
-122500000 USD
CY2020Q2 rvnc Working Capital Surplus
WorkingCapitalSurplus
454800000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-966700000 USD
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
494000000.0 USD
rvnc Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum
CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum
P12M
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition, deferred revenue classification, accruals including clinical trial costs, stock-based compensation, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration of asset acquisitions, and accounting for income taxes. We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 has caused a global slowdown of economic activity which has decreased demand for a broad variety of goods and services, including from our potential customers, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic on, for instance, clinical trials and product launch timing. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.</span></div>
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
31000000.0 USD
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
31000000.0 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
470050000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
117000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
470167000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
282686000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
282683000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
470167000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
282686000 USD
CY2019 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
11200000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
800000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2020Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P14Y
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1425000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1425000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
2850000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
2768000 USD
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
272000 USD
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
298000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
349000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
588000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.120
CY2020Q2 us-gaap Lease Cost
LeaseCost
1697000 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
1723000 USD
us-gaap Lease Cost
LeaseCost
3199000 USD
us-gaap Lease Cost
LeaseCost
3356000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3372000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6942000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5464000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5557000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5733000 USD
CY2020Q2 rvnc Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
12226000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
39294000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11634000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
27660000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3890000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
3363000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
3069000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2020Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1258000 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1901000 USD
CY2020Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2909000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4370000 USD
CY2020Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
90000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
134000 USD
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4257000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
6405000 USD
CY2020Q1 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
28900000 USD
CY2020Q1 rvnc Capped Calls Price Cap
CappedCallsPriceCap
48.88
CY2020Q1 rvnc Capped Calls Premium Percentage Over Sale Price
CappedCallsPremiumPercentageOverSalePrice
1
CY2020Q1 rvnc Capped Calls Number Of Shares Subject To Antidilution Adjustments
CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments
8900000 shares
CY2020Q1 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
28900000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7353000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4420000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13897000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8579000 USD
rvnc Indemnification Liability Recordedduring Period
IndemnificationLiabilityRecordedduringPeriod
0 USD
CY2020Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
285000000.0 USD

Files In Submission

Name View Source Status
0001479290-20-000090-index-headers.html Edgar Link pending
0001479290-20-000090-index.html Edgar Link pending
0001479290-20-000090.txt Edgar Link pending
0001479290-20-000090-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imgexhibit10811.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvnc-20200630.htm Edgar Link pending
rvnc-20200630.xsd Edgar Link pending
rvnc-20200630_cal.xml Edgar Link unprocessable
rvnc-20200630_def.xml Edgar Link unprocessable
rvnc-20200630_htm.xml Edgar Link completed
rvnc-20200630_lab.xml Edgar Link unprocessable
rvnc-20200630_pre.xml Edgar Link unprocessable
rvncq22010-qexhibit101.htm Edgar Link pending
rvncq22010-qexhibit311.htm Edgar Link pending
rvncq22010-qexhibit312.htm Edgar Link pending
rvncq22010-qexhibit321.htm Edgar Link pending
rvncq22010-qexhibit322.htm Edgar Link pending
Show.js Edgar Link pending